Начало・Списък с акции・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Затворен

СекторЗдравеопазване

2.97 -1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.94

Максимум

3.16

Ключови измерители
By Trading Economics
Приходи	454K -5M
EPS	-0.08
Служители	9
EBITDA	474K -3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+270.37% upside

Дивиденти
By Acuity
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	77M 223M
Предишно отваряне	3.97
Предишно затваряне	2.97

Настроения в новините

By Acuity

25%

75%

73 / 340 Класиране в Healthcare

Galectin Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:46 ч. UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31.07.2026 г., 21:51 ч. UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30.07.2026 г., 20:10 ч. UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29.07.2026 г., 18:58 ч. UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28.07.2026 г., 17:46 ч. UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27.07.2026 г., 16:32 ч. UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24.07.2026 г., 20:02 ч. UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22.07.2026 г., 19:01 ч. UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21.07.2026 г., 17:16 ч. UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20.07.2026 г., 20:06 ч. UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Сравнение с други в отрасъла

Ценова промяна

Galectin Therapeutics Inc Прогноза

Ценова цел

By TipRanks

270.37% нагоре

12-месечна прогноза

Среден 11 USD 270.37%

Висок 11 USD

Нисък 11 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Galectin Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Galectin Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

73 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.